Intended for healthcare professionals

Research Methods & Reporting

Good publication practice for communicating company sponsored medical research: the GPP2 guidelines

BMJ 2009; 339 doi: (Published 30 November 2009) Cite this as: BMJ 2009;339:b4330
  1. Chris Graf, associate editorial director 1,
  2. Wendy P Battisti, associate director, scientific and medical publications2,
  3. Dan Bridges, group programme director3,
  4. Victoria Bruce-Winkler, medical publications consultant4,
  5. Joanne M Conaty, senior director, clinical strategy and planning5,
  6. John M Ellison, senior manager, scientific publications6,
  7. Elizabeth A Field, president7,
  8. James A Gurr, director, publication planning and development8,
  9. Mary-Ellen Marx, senior manager, medical education9,
  10. Mina Patel, senior director, medical communications10,
  11. Carol Sanes-Miller, global publications manager, scientific communications5,
  12. Yvonne E Yarker, senior vice president, medical communications11,
  13. for the International Society for Medical Publication Professionals
  1. 1John Wiley & Sons, Wiley-Blackwell, Oxford OX4 2DQ
  2. 2Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA
  3. 3Excerpta Medica, Elsevier, London
  4. 4Dunblane
  5. 5AstraZeneca Pharmaceuticals, Wilmington, DE, USA
  6. 6LifeScan, Milpitas, CA, USA
  7. 7Field Advantage Medical Communications, Chapel Hill, NC, USA
  8. 8Pfizer Collegeville, PA, USA
  9. 9PharmaWrite, Princeton, NJ, USA
  10. 10Cephalon, Frazer, PA, USA
  11. 11Knowledgepoint 360 Group, Newtown, PA, USA
  1. Correspondence to: C Graf chris.graf{at}
  • Accepted 13 October 2009

In response to changes in the environment in which authors, presenters, and other contributors work together to communicate medical research the International Society for Medical Publication Professionals has updated the good publication practice guidelines

Authors and presenters are responsible for how medical research is interpreted and communicated. Often their work is the product of collaborations with other individuals (such as clinical investigators, biostatisticians, and professional medical writers) from around the world. Some or all of the people who contribute to this collaboration may be employees of research sponsors, contract research organisations, or medical communications agencies that may be funded by pharmaceutical, medical device, or biotechnology companies. The authors, collaborators, and organisations share responsibility for developing articles and presentations in a responsible and ethical manner.

The good publication practice (GPP2) guidelines presented here make recommendations that will help individuals and organisations maintain ethical practices and comply with current requirements when they contribute to the communication of medical research sponsored by companies. These guidelines apply to peer reviewed journal articles and presentations at scientific congresses.

What’s new?

GPP2 updates earlier good publication practice guidelines.6

New elements include:

  • An extensive consultation process was used to write the guidelines

  • Authorship guidance recommends assignment of a lead author and guarantor

  • Contributorship guidance recommends describing the role of the sponsor

  • Recommendations about reimbursement

  • Recommendations for specific types of articles and presentations

  • Recommendations for publication planning and documentation

Updated elements include:

  • Guidance on defining the roles of authors, sponsors, and other contributors

  • Guidance on establishing a publication steering committee

  • Confirmation of the role of professional medical writers

Evolving standards

The conduct and communication of medical research, including that sponsored by companies, continues to be criticised.1 2 3 4 5 Since 2003, when the original good publication practice guidelines were published,6 the environment in which medical research is reported …

View Full Text